A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection

Sitagliptin and Immune Activation in HIV • CID 2019:69 (1 October) • 1165 Received 16 October 2018; editorial decision 21 November 2018; accepted 5 December 2018; published online December 10, 2018. Correspondence: M. P. Dubé, Keck School of Medicine, University of Southern California, 1300 N Mission Rd, Rm 349, Los Angeles, CA 90033 (mdube@usc.edu). Clinical Infectious Diseases 2019;69(7):1165–72 © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. DOI: 10.1093/cid/ciy1051 A Randomized, Double-blinded, Placebo-controlled Trial of Sitagliptin for Reducing Inflammation and Immune Activation in Treated and Suppressed Human Immunodeficiency Virus Infection